[Tree] Updates on Sutro Biopharma and Ipsen's partnership, Telix Pharmaceuticals Q2 2024 revenue increase
Version 0.17 (2024-07-18 16:49:47.834000)
updates: Includes updates on Telix Pharmaceuticals Q2 2024 revenue increase
- ➔
- ➔
Version 0.16 (2024-04-03 12:22:33.995000)
updates: Piper Sandler lowers Sutro Biopharma's price target
- ➔
Version 0.15 (2024-04-03 09:23:18.874000)
updates: Roth/MKM raises Virtra's price target to $19.00
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.14 (2024-04-01 19:24:10.724000)
updates: Oppenheimer adjusts price target for Zura Bio
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.13 (2024-04-01 18:24:04.752000)
updates: H.C. Wainwright increases price target on Akebia Therapeutics after FDA approval of Vafseo
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.12 (2024-03-27 22:27:42.087000)
updates: Aptose Biosciences faces lowered stock price target but maintains buy rating as it shifts focus to new drug combination for AML treatment
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.11 (2024-03-19 17:23:37.750000)
updates: Caribou Biosciences receives raised price target of $24 from H.C. Wainwright
- ➔
- ➔
- ➔
- ➔
Version 0.1 (2024-03-19 14:27:21.853000)
updates: Add information about UBS raising Oxford Industries shares target
- ➔
- ➔
- ➔
Version 0.08 (2024-03-02 21:25:22.666000)
updates: Puma Biotechnology's price target lowered by HC Wainwright
- ➔
Version 0.07 (2024-03-01 15:10:19.478000)
updates: Puma's embrace of new technology platforms like Roblox, NFTs, and virtual reality to connect with audiences
- ➔
- ➔
- ➔
- ➔
Version 0.06 (2024-02-02 15:23:06.632000)
updates: Columbia Sportswear stock downgrade and brand slowdown
- ➔
- ➔
- ➔
Version 0.05 (2023-11-11 00:25:18.462000)
updates: Restructured and combined information from multiple sources
- ➔
- ➔
Version 0.04 (2023-11-10 19:24:20.739000)
updates: Added information about other companies' earnings
- ➔
- ➔
Version 0.03 (2023-10-24 21:08:10.762000)
updates: The title is more concise and the story is condensed with relevant details.
- ➔
Version 0.02 (2023-10-23 18:22:26.192000)
updates: The narrative provides an analysis of the third-quarter earnings season and UBS's expectations for S&P 500 earnings growth.
- ➔